ARTICLE | Company News
Leo buys Astellas' dermatology business
November 12, 2015 1:29 AM UTC
Leo Pharma A/S (Ballerup, Denmark) will acquire the global dermatology business of Astellas Pharma Inc. (Tokyo:4503) for EUR 675 million ($726.6 million).
Astellas' dermatology portfolio includes Protopic, a topical formulation of immunosuppressant tacrolimus to treat eczema, as well as dermatitis treatment Locoid hydrocortisone butyrate. Leo markets treatments for psoriasis and acne. Leo will not acquire Japan rights to Protopic, which Maruho Co. Ltd. (Osaka, Japan) holds. ...